Talaris Therapeutics, Inc. (TALS): Price and Financial Metrics

Talaris Therapeutics, Inc. (TALS): $27.20

0.20 (-0.73%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add TALS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#127 of 360

in industry

TALS Price/Volume Stats

Current price $27.20 52-week high $27.95
Prev. close $2.74 52-week low $0.89
Day low $26.90 Volume 30,520
Day high $27.95 Avg. volume 386,531
50-day MA $2.83 Dividend yield N/A
200-day MA $2.41 Market Cap 1.16B

TALS Stock Price Chart Interactive Chart >


Talaris Therapeutics, Inc. (TALS) Company Bio


Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.


TALS Latest News Stream


Event/Time News Detail
Loading, please wait...

TALS Latest Social Stream


Loading social stream, please wait...

View Full TALS Social Stream

Latest TALS News From Around the Web

Below are the latest news stories about TALARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate TALS as an investment opportunity.

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris’ stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris’ common stock to the stockholders of Tourm

Yahoo | October 17, 2023

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Tourmaline Bio, Inc. (“Tourmaline”) pursuant to the Agreement and Plan of Merger, da

Yahoo | October 6, 2023

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

This acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organizationNEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain techn

Yahoo | October 4, 2023

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | September 12, 2023

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) Combined company expected to have approximately $210 million of cash at the transaction close, including approximately $75 million from a concurrent private placement with leading life sciences investors Strong balance sheet expected to support three clinical trials for TOUR006 inc

Yahoo | June 22, 2023

Read More 'TALS' Stories Here

TALS Price Returns

1-mo N/A
3-mo N/A
6-mo -3.20%
1-year 51.96%
3-year N/A
5-year N/A
YTD N/A
2023 0.00%
2022 -93.33%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!